ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Curis Announces Positive Data in Ongoing Study of Fimepinostat, Venetoclax Combo
December 12, 2019Curis announced preliminary tolerability and PK data from its ongoing Phase 1 dose-finding study of fimepinostat, a small molecule dual inhibitor of PI3K/HDAC and suppressor of MYC ... -
Curis moves up COO as CEO Fattaey leaves company
September 27, 2018James Dentzer has been leading the company’s pre-commercial planning for fimepinostat, which received an FDA fast-track designation in relapsed or refractory diffuse large B-cell lymphoma in May.
Pharma Sources Insight January 2025
